SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

PALISADE BIO, INC.
Date: Aug. 21, 2025 · CIK: 0001357459 · Accession: 0000000000-25-008915

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289635

Date
August 21, 2025
Author
Division of
Form
UPLOAD
Company
PALISADE BIO, INC.

Letter

Re: Palisade Bio, Inc. Registration Statement on Form S-3 Filed August 15, 2025 File No. 333-289635 Dear J.D. Finley:

August 21, 2025

J.D. Finley Chief Executive Officer Palisade Bio, Inc. 1902 Wright Place, Suite 200 Carlsbad, CA 92008

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: John E. Maciejewski

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 21, 2025

J.D. Finley
Chief Executive Officer
Palisade Bio, Inc.
1902 Wright Place, Suite 200
Carlsbad, CA 92008

 Re: Palisade Bio, Inc.
 Registration Statement on Form S-3
 Filed August 15, 2025
 File No. 333-289635
Dear J.D. Finley:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Joshua Gorsky at 202-551-7836 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: John E. Maciejewski
</TEXT>
</DOCUMENT>